Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Inc. and Agios Pharmaceuticals, Inc.

Community Practice Connection: Emerging Applications to Optimize and Individualize AML Treatment

Release Date: August 31, 2020
Expiration Date: August 31, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in acute myeloid leukemia (AML) for an in-depth discussion examining the latest data related to treatment strategies and their implications for the clinical management of patients with AML. Novel treatment strategies and clinical applications will be covered in the context of highlighting consequential emerging data and evidence-based best practices for optimizing patient outcomes. The innovative, engaging format includes interviews with expert faculty in the field. Future directions in research and treatment options will also be addressed and considered related to how recent developments and highly anticipated trials may shape clinical care.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc. and Agios Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with AML. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with AML are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Utilize clinical, genomic, and molecular criteria to diagnose, characterize mutations, and assess risk in patients with AML
  • Integrate clinical evidence for recently approved therapeutic agents into current treatment paradigms across the continuum of care for patients with AML
  • Optimize and individualize treatment selection for patients with AML in frontline and relapsed/refractory settings, including elderly patients and those unfit for intensive induction regimens
  • Review ongoing investigational studies designed to evaluate novel therapies for AML in the context of unmet clinical needs and clinical trial opportunities for appropriate patients
  • Implement appropriate strategies for recognizing and managing potential treatment-related toxicities in patients undergoing therapy for AML

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.


William Oh, MD
Gail J. Roboz, MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
The New York-Presbyterian Hospital
New York, NY

Disclosures: Grant Research Support: Cellectis; Consultant: Consultancy or Advisory Board or Data and Safety Monitoring Committee: AbbVie, Inc; Actinium Pharmaceuticals, Inc; Agios
Pharmaceuticals, Inc; Amphivena Therapeutics; argenx; Array BioPharma, Inc; Astex Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Celgene; Celltrion; Daiichi Sankyo; Eisai Co, Ltd; Epizyme; Helsinn Therapeutics, Inc; Janssen; Jasper Therapeutics, Inc; Jazz Pharmaceuticals; Independent Data Monitoring Committee Chair: MEI Pharma, Inc; Novartis; Orsenix; Otsuka; Pfizer; Roche/Genentech; Sandoz; Independent Review Committee
Chair: Takeda; Trovagene (now Cardiff Oncology)

Lindsay Diamond, NP, MSN, OCN
Courtney D. DiNardo, MD, MSCE
Associate Professor of Medicine
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: AbbVie, Inc; Agios Pharmaceuticals, Inc; Celgene; Consultant: AbbVie, Inc; Agios Pharmaceuticals, Inc; Celgene; Daiichi Sankyo; Novartis; Notable Labs; Shareholder: Notable Labs (scientific advisory board with stock options)

Lindsay Diamond, NP, MSN, OCN
Jeffrey E. Lancet, MD
Senior Member and Professor
Chair, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Disclosures: Consultant: Agios Pharmaceuticals, Inc; Astellas Pharma; Daiichi Sankyo; ElevateBio; Jazz Pharmaceuticals

Lindsay Diamond, NP, MSN, OCN
Alexander Perl, MD
Associate Professor of Medicine
Leukemia Program
Division of Hematology Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: AbbVie, Inc; Astellas Pharma; Daiichi Sankyo; Fujifilm; Bayer; Consultant: AbbVie, Inc; Astellas Pharma; Daiichi Sankyo; Actinium Pharmaceuticals, Inc; Forma Therapeutics; Other: honoraria: Syndax; Loxo Oncology.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant as a substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By